Skip to main content
SpringerLink
Log in

Ranibizumab cost effective for AMD in Austria

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Walter E, Brennig C, Moeremans K, Thomas V.Pharmacoeconomic evaluation of ranibizumab in the treatment of age-related macular degeneration in Austria. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 617 abstr. PSS26, 8 Nov 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ranibizumab cost effective for AMD in Austria. Pharmacoecon. Outcomes News 567, 3 (2008). https://doi.org/10.2165/00151234-200805670-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805670-00003

Keywords

Search

Navigation